

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1276)

CLOSURE OF THE H SHARE REGISTER OF MEMBERS FOR THE 2026 FIRST EXTRAORDINARY SHAREHOLDERS' MEETING

Reference is made to the announcement of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) dated August 19, 2026 in relation to the proposed adoption of the 2026 H Share Scheme (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company will convene and hold the 2026 first extraordinary shareholders' meeting (the “**Shareholders' Meeting**”) at 2:30 p.m. on Thursday, September 24, 2026 at No. 1288, Haik Road, Pudong New Area, Shanghai, PRC to consider and, if thought fit, approve, among other matters, the proposed adoption of the 2026 H Share Scheme.

For the purpose of determining the list of holders of H Shares who are entitled to attend the Shareholders' Meeting, the H Share register of members of the Company will be closed from Monday, September 21, 2026 to Thursday, September 24, 2026, both dates inclusive, during which period no transfer of H Shares will be registered. The record date will be Thursday, September 24, 2026. In order to be eligible to attend and vote at the Shareholders' Meeting, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Friday, September 18, 2026 for registration.

A circular containing, among other things, further information in relation to the matters to be considered at the Shareholders' Meeting, together with the notice of the Shareholders' Meeting, will be published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.hengrui.com) in due course.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
September 7, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.